Indoco Remedies (INDOCO) | Financial Analysis & Statements
Indoco Remedies Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
4.3B
Gross Profit
2.9B
68.54%
Operating Income
-121.7M
-2.84%
Net Income
-363.5M
-8.47%
EPS (Diluted)
₹-3.94
Balance Sheet Metrics
Total Assets
24.3B
Total Liabilities
14.1B
Shareholders Equity
10.2B
Debt to Equity
1.39
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Indoco Remedies Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 16.4B | 17.9B | 16.4B | 15.0B | 12.2B |
| Cost of Goods Sold | 5.1B | 5.8B | 5.4B | 4.8B | 3.7B |
| Gross Profit | 11.3B | 12.1B | 11.0B | 10.2B | 8.5B |
| Gross Margin % | 68.7% | 67.4% | 67.1% | 68.1% | 69.6% |
| Operating Expenses | |||||
| Research & Development | 760.1M | 971.6M | 809.7M | 746.4M | 597.0M |
| Selling, General & Administrative | 2.6B | 2.1B | 1.7B | 1.4B | 1.3B |
| Other Operating Expenses | 3.1B | 3.0B | 2.6B | 2.2B | 1.6B |
| Total Operating Expenses | 6.5B | 6.1B | 5.1B | 4.3B | 3.5B |
| Operating Income | -267.2M | 1.4B | 2.0B | 2.2B | 1.6B |
| Operating Margin % | -1.6% | 8.0% | 12.1% | 14.6% | 13.1% |
| Non-Operating Items | |||||
| Interest Income | 8.4M | 39.6M | 5.8M | 4.7M | 7.9M |
| Interest Expense | 620.3M | 370.8M | 237.5M | 164.6M | 210.4M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -743.7M | 1.4B | 1.9B | 2.4B | 1.3B |
| Income Tax | 35.8M | 387.9M | 505.4M | 817.7M | 389.5M |
| Effective Tax Rate % | 0.0% | 28.6% | 26.2% | 34.6% | 29.5% |
| Net Income | -779.5M | 970.0M | 1.4B | 1.5B | 930.5M |
| Net Margin % | -4.7% | 5.4% | 8.7% | 10.3% | 7.6% |
| Key Metrics | |||||
| EBITDA | 1.0B | 2.6B | 2.9B | 3.3B | 2.4B |
| EPS (Basic) | ₹-8.00 | ₹10.53 | ₹15.44 | ₹16.80 | ₹10.10 |
| EPS (Diluted) | ₹-8.00 | ₹10.51 | ₹15.42 | ₹16.80 | ₹10.10 |
| Basic Shares Outstanding | 92194805 | 92150616 | 92150355 | 92150355 | 92124257 |
| Diluted Shares Outstanding | 92194805 | 92150616 | 92150355 | 92150355 | 92124257 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Indoco Remedies Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 121.0M | 148.6M | 109.2M | 174.7M | 94.2M |
| Short-term Investments | 32.2M | 107.4M | 39.9M | 241.5M | 21.0M |
| Accounts Receivable | 3.5B | 4.1B | 3.5B | 3.0B | 2.3B |
| Inventory | 4.2B | 3.5B | 3.3B | 3.1B | 2.4B |
| Other Current Assets | 1.9B | 1.5B | 1.1B | 1.2B | 59.0K |
| Total Current Assets | 10.0B | 9.5B | 8.1B | 7.7B | 6.2B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 3.5B | 3.2B | 2.9B | 2.5B | 2.4B |
| Goodwill | 2.1B | 2.1B | 1.2B | 920.6M | 846.9M |
| Intangible Assets | 1.7B | 1.7B | 1.2B | 918.8M | 845.1M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 6.0K | 996.6M | 465.0M | 325.7M | 211.8M |
| Total Non-Current Assets | 14.3B | 11.9B | 8.4B | 7.1B | 6.9B |
| Total Assets | 24.3B | 21.4B | 16.6B | 14.9B | 13.2B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 2.1B | 1.5B | 1.2B | 1.3B | 1.1B |
| Short-term Debt | 4.5B | 3.1B | 1.7B | 1.5B | 1.6B |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 231.6M | 9.5M | 572.9M | 856.9M | 761.2M |
| Total Current Liabilities | 8.1B | 6.1B | 4.2B | 4.2B | 4.1B |
| Non-Current Liabilities | |||||
| Long-term Debt | 5.4B | 3.6B | 1.6B | 1.1B | 1.0B |
| Deferred Tax Liabilities | 133.6M | 118.3M | 61.4M | 106.0M | 0 |
| Other Non-Current Liabilities | 74.1M | 73.6M | 73.6M | 74.1M | 74.3M |
| Total Non-Current Liabilities | 6.0B | 4.2B | 2.1B | 1.6B | 1.4B |
| Total Liabilities | 14.1B | 10.3B | 6.3B | 5.8B | 5.5B |
| Equity | |||||
| Common Stock | 184.5M | 184.4M | 184.3M | 184.3M | 184.3M |
| Retained Earnings | 6.7B | 7.6B | 6.9B | 5.6B | 4.3B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 10.2B | 11.1B | 10.3B | 9.0B | 7.7B |
| Key Metrics | |||||
| Total Debt | 9.9B | 6.7B | 3.3B | 2.6B | 2.7B |
| Working Capital | 1.9B | 3.4B | 3.9B | 3.5B | 2.2B |
Balance Sheet Composition
Indoco Remedies Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -753.6M | 1.2B | 1.9B | 2.4B | 1.3B |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 22.0M | 28.8M | 6.6M | 0 | - |
| Working Capital Changes | -446.8M | -1.2B | -702.0M | -1.3B | -875.9M |
| Operating Cash Flow | -532.2M | 444.7M | 1.5B | 1.2B | 647.3M |
| Investing Activities | |||||
| Capital Expenditures | 38.0M | 16.8M | 11.6M | 9.4M | 2.0M |
| Acquisitions | 0 | - | - | - | - |
| Investment Purchases | 0 | -126.7M | -25.5M | -15.0K | 0 |
| Investment Sales | 79.0M | - | - | - | - |
| Investing Cash Flow | 162.0M | -174.2M | -14.9M | 35.5M | 94.5M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -139.0M | -207.1M | -207.2M | -137.9M | -27.9M |
| Debt Issuance | 2.6B | 2.5B | 950.0M | 975.0M | 365.0M |
| Debt Repayment | -417.3M | -490.4M | -406.2M | -979.0M | -508.4M |
| Financing Cash Flow | 3.1B | 3.2B | 517.7M | -281.0M | -58.8M |
| Free Cash Flow | -2.6B | -2.7B | -284.2M | 485.0M | 53.7M |
| Net Change in Cash | 2.7B | 3.5B | 2.0B | 984.8M | 683.0M |
Cash Flow Trend
Indoco Remedies Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
101.34
Forward P/E
34.83
Price to Book
1.73
Price to Sales
1.12
PEG Ratio
26.01
Profitability Ratios
Profit Margin
-6.47%
Operating Margin
-0.11%
Return on Equity
-7.24%
Return on Assets
-3.03%
Financial Health
Current Ratio
1.10
Debt to Equity
102.50
Beta
0.44
Per Share Data
EPS (TTM)
₹-12.17
Book Value per Share
₹123.55
Revenue per Share
₹181.60
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| INDOCO | 18.9B | 101.34 | 1.73 | -7.24% | -6.47% | 102.50 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





